281 related articles for article (PubMed ID: 24127768)
1. The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.
Wu S; Sun F; Zhang Y; Yang Z; Hong T; Chen Y; Zhan S
J Clin Pharm Ther; 2014 Feb; 39(1):7-13. PubMed ID: 24127768
[TBL] [Abstract][Full Text] [Related]
2. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
[TBL] [Abstract][Full Text] [Related]
3. Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials.
Mabilleau G; Mieczkowska A; Chappard D
J Diabetes; 2014 May; 6(3):260-6. PubMed ID: 24164867
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis.
Sun F; Yu K; Wu S; Zhang Y; Yang Z; Shi L; Ji L; Zhan S
Diabetes Res Clin Pract; 2012 Dec; 98(3):386-95. PubMed ID: 23020934
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
[TBL] [Abstract][Full Text] [Related]
10. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
11. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
Mannucci E; Dicembrini I; Nreu B; Monami M
Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
15. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials.
Wang Y; Li L; Yang M; Liu H; Boden G; Yang G
Diabetes Obes Metab; 2011 Nov; 13(11):972-81. PubMed ID: 21651690
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
18. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
19. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
20. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
